^
    Back
    Association details:
    Biomarker:EGFR wild-type + MET wild-type
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Biochem Pharmacol
    Title:

    Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

    Published date:
    05/10/2019
    Excerpt:
    we investigated the efficacy of a dual blockade with erlotinib and crizotinib in EGFR and cMET wild-type lung SCC cell lines....Erlotinib and crizotinib showed additive interaction in Calu1, H520 and SKMES-1, and strong synergism in the LUDLU cells (Combination Index: 0.387), associated to G2/M phase arrest, increased apoptosis, spheroid size reduction and inhibition of migration....Combining erlotinib and crizotinib led to an additive/synergistic interaction in 4 out of 5 SCC cells.
    DOI:
    10.1016/j.bcp.2019.05.014